PIFELTRO

Peak

doravirine

NDAORALTABLET
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

Non-Nucleoside Reverse Transcriptase Inhibitors

Pharmacologic Class:

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Clinical Trials (5)

NCT07086079Phase 1Completed

A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)

Started Sep 2025
12 enrolled
Healthy
NCT04820933Phase 1Completed

Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV

Started Mar 2024
26 enrolled
HIV I InfectionCardiovascular Risk FactorLipid Metabolism Disorders
NCT06719570Phase 1Completed

A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)

Started Jan 2024
24 enrolled
Healthy
NCT05761509N/ACompleted

"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"

Started Jun 2023
226 enrolled
HIV Infections
NCT05766501Phase 3Active Not Recruiting

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)

Started Mar 2023
641 enrolled
HIV Infection

Loss of Exclusivity

LOE Date
Aug 30, 2032
78 months away
Patent Expiry
Aug 30, 2032

Patent Records (1)

Patent #ExpiryTypeUse Code
8486975
Aug 30, 2032
SubstanceProduct
U-3308